The intravenous drug can be used as a short-term replacement therapy for patients with certain types of seizure disorders when oral administration of the drug is not possible.
San Diego, Calif.-based Ligand Pharmaceuticals, a partner of Lundbeck, will earn a $1.25 million milestone payment for the approval and is entitled to 2.75 percent of Carnexiv’s net sales.
Lundbeck plans to launch Carnexiv in early 2017.
More articles on supply chain:
Southwest Airlines to haul international cargo next year
Dana-Farber, Brigham and Women’s in ‘urgent need’ of platelet donations
Southwest Airlines to haul international cargo next year
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
